BACKGROUND:

Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented.

METHODS:

Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively.

RESULTS:

Sidedness was determined in 1590 (27% right and 73% left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95% CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95% CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95% CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95% CI 0.74, 0.98; p = 0.028).

CONCLUSIONS:

This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.